EUVIMEDDescubrir EUVIMED
Open access · CC BY 4.0

TNF Pathway‐Mediated Tolerogenic T‐Cell Trajectory Driven by Allergen Immunotherapy

Helen S Charles, Amr A Gabr, Shu-Hung Wang, Ulrich M Zissler, Sonja Heine, Alexander Heldner, Sebastian Kotz, Lisa Pechtold, Lynn S Zur Bonsen, Dimitrii Pogorelov, Josephine Kau, Mirjam Plaschke and 9 more

Allergy · 2026-06 · 81 (6) · 2184-2197

DOI: 10.1111/all.70367 ↗

At a glance

Journal article in Allergy, published online on 2026-04-30. Written by Helen S Charles and 20 co-authors. Institution: Center of Allergy and Environment (ZAUM), School of Medicine and Health, Technical University of Munich and Helmholtz Munich, Munich, Germany. Major MEDLINE topics: Desensitization, Immunologic, Immune Tolerance, Signal Transduction, Tumor Necrosis Factor-alpha. 37 references. The full text is freely available (open access, CC BY 4.0).

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Background

Allergen immunotherapy (AIT) is a therapeutic approach to restore allergen tolerance and prevent asthma progression. Previous studies have shown exhaustion of T cells and the induction of T cells expressing IL‐17 and FOXP3 early in AIT, which are relevant for the clinical outcome. This study aims to investigate the dynamic transition from type‐3 immunity to a regulatory state observed in the first year during allergic inflammation, as well as the subsequent dysfunction of effector cells during AIT.

Methods

Human and experimental models of allergic airway inflammation were used to assess the impact of AIT on Treg, Tr17 and Th17 cell populations using flow cytometry and proliferation assays. Additionally, human blood samples were analysed using single‐cell transcriptomics to characterise transcriptional signatures associated with the transition from pro‐inflammatory to regulatory states.

Results

AIT restored balance of Tr17 and Treg populations and increased their proliferative capacity, whereas Th17 cells remained functionally impaired. Single‐cell transcriptomics identified Tr17 cells as intermediate states between pro‐inflammatory and regulatory T‐cell programs after AIT. In parallel, AIT reprogrammed intracellular communication networks, with TNF/LTA‐associated signalling pathways emerging as prominent mediators of tolerogenic signalling.

Conclusion

These findings highlight that AIT reprograms immune responses by enhancing regulatory dominance, inducing Tr17 plasticity and leveraging TNF/TNFR2‐mediated tolerance. Understanding the cellular dynamics during AIT suggests that therapeutic strategies aimed at targeting Th17 functional impairment could further enhance treatment efficacy for allergic airway diseases. This insight opens new avenues for refining immunotherapeutic approaches to more effectively restore immune balance and improve patient outcomes.

Subjects

MeSH terms (MEDLINE)

Desensitization, ImmunologicImmune ToleranceSignal TransductionTumor Necrosis Factor-alphaT-Lymphocyte SubsetsT-LymphocytesHumansAnimalsT-Lymphocytes, RegulatoryTh17 CellsAllergensMiceHypersensitivity

Author keywords

T cellsTh17 cellsallergen immunotherapyexhaustiontrans‐differentiation

Substances

Tumor Necrosis Factor-alphaAllergens

Authors and institutions

  • Center of Allergy and Environment (ZAUM), School of Medicine and Health, Technical University of Munich and Helmholtz Munich, Munich, Germany.
  • German Center for Lung Research (DZL), Giessen, Germany.
  • Department of Physiology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
  • Department of Otorhinolaryngology, TUM School of Medicine and Health, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
  • Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.

ORCID profiles: Carsten B Schmidt-Weber, Constanze A Jakwerth

Cite

APA

Charles, H. S., Gabr, A. A., Wang, S. H., Zissler, U. M., Heine, S., Heldner, A., Kotz, S., Pechtold, L., Bonsen, L. S. Z., Pogorelov, D., Kau, J., Plaschke, M., Hills, M., Guerth, F., Oelsner, M., Ohnmacht, C., Alessandrini, F., Blank, S., Chaker, A. M., …, & Jakwerth, C. A. (2026). TNF Pathway‐Mediated Tolerogenic T‐Cell Trajectory Driven by Allergen Immunotherapy. Allergy, 81(6), 2184-2197. https://doi.org/10.1111/all.70367

Vancouver

Charles HS, Gabr AA, Wang SH, Zissler UM, Heine S, Heldner A, et al. TNF Pathway‐Mediated Tolerogenic T‐Cell Trajectory Driven by Allergen Immunotherapy. Allergy. 2026;81(6):2184-2197. doi:10.1111/all.70367

BibTeX
@article{Charles2026,
  author = {Charles, Helen S and Gabr, Amr A and Wang, Shu-Hung and Zissler, Ulrich M and Heine, Sonja and Heldner, Alexander and Kotz, Sebastian and Pechtold, Lisa and Bonsen, Lynn S Zur and Pogorelov, Dimitrii and Kau, Josephine and Plaschke, Mirjam and Hills, Miriam and Guerth, Ferdinand and Oelsner, Madlen and Ohnmacht, Caspar and Alessandrini, Francesca and Blank, Simon and Chaker, Adam M and Schmidt-Weber, Carsten B and Jakwerth, Constanze A},
  title = {TNF Pathway‐Mediated Tolerogenic T‐Cell Trajectory Driven by Allergen Immunotherapy},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {6},
  pages = {2184--2197},
  doi = {10.1111/all.70367}
}
Start for free →